



Ivabradine (Procoralan®)

Servier Laboratories Ltd

January 2010

Appraisal notice to NHS Wales

Ivabradine (Procoralan®) has not been endorsed for use within NHS Wales for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease in combination with beta blockers in patients inadequately controlled with an optimal beta blocker dose and whose heart rate is >60bpm (licence extension).

The holder of the marketing authorisation is not in a position to progress a submission to AWMSG for the appraisal of ivabradine (Procoralan®) for the above indication. As a result, AWMSG cannot provide advice to the Minister for Health and Social Services.

AWMSG takes into account the NICE future work programme when considering whether a product will be appraised. To avoid duplication of effort, AWMSG would not normally consider undertaking an appraisal if NICE intend to publish final advice of the same product within twelve months of the projected Form B submission date. AWMSG advice is interim to that of NICE, should NICE subsequently publish guidance.

This notice is provided for information to NHS Wales. In the absence of guidance issued by NICE or AWMSG, clinicians should continue to exercise their clinical judgement when providing care for an individual patient. This should be in consultation with the patient and/or guardian or carer, based on the best available evidence.

This notice will be removed on receipt of a full submission (i.e. Form A and B)